Milestones

Discovery & Breakthroughs: Every Step from Original Innovation to Clinical Translation

2016

  • Leonurine Sulfate (SCM-198), developed under the leadership of Professor Zhu Yizhun, successfully transferred for RMB 150 million
  • Professor Zhu Yizhun’s team first proposed CSE (Cystathionine γ-lyase) as a novel therapeutic target for rheumatoid arthritis in ELSEVIER, a world-renowned academic journal
2018

  • Leonurine Sulfate (SCM-198) advanced with dual filings in China and the US, progressively entering Phase I/II clinical trials
  • Innovative target HDAC4 recognized as “ushering in a new era of vascular inflammation research”
  • Innovative target JMJD3 recognized as “unveiling the emperor’s new clothes in vascular injury research”
2019

  • Novel compounds with proprietary intellectual property—SPRC (Propargylcysteine, also known as ZYZ-802) and JMJD3 inhibitor as a new mechanism for treating rheumatoid arthritis—published in Nature sub-journal
2020-2021

  • Professor Zhu Yizhun led research on innovative target SMYD3 published in top-tier journals Aging Cell/Aging/ATVB
2022

  • CSE (Cystathionine γ-lyase), proposed by Professor Zhu Yizhun’s research team, selected as one of the Top 10 Drug Targets by Science in 2022
2024

  • During his inspection visit to Macao, President Xi Jinping visited the State Key Laboratory of Quality Research in Chinese Medicines at Macao University of Science and Technology, led by Professor Zhu Yizhun.
  • Awarded First Place at the 13th Innovation & Entrepreneurship Competition
2025

  • First-in-class drug ZYZ-802 completed preclinical studies, filed as a first-in-class drug, and entered Phase I clinical trials
  • First-in-class drug Leonurine Sulfate (SCM-198) successfully reacquired and entered Phase II clinical trials